Hypothyroidism and Hyperthyroidism: Pathophysiology, Pharmacology, and Clinical Management

In a busy internal medicine clinic, a 45‑year‑old woman presents with fatigue, weight gain, and a tremor that has worsened over the past month. A routine thyroid panel reveals an elevated TSH and low free T4, confirming hypothyroidism. Such cases are commonplace, yet the therapeutic journey—from diagnosis to drug selection—requires a nuanced understanding of thyroid physiology, pharmacodynamics, and patient‑specific factors. This article delves into the intricate world of hypo‑ and hyperthyroidism, offering a comprehensive review that balances evidence‑based medicine with exam‑ready insights.

Introduction and Background

Thyroid disorders rank among the most frequent endocrine abnormalities worldwide, affecting up to 5% of the adult population in developed countries. Hypothyroidism, characterized by insufficient synthesis or release of thyroid hormones, can arise from autoimmune destruction (Hashimoto’s thyroiditis), iodine deficiency, or iatrogenic causes such as thyroidectomy. Conversely, hyperthyroidism, marked by excess hormone production, is most commonly due to Graves’ disease, toxic multinodular goiter, or toxic adenoma. The clinical spectrum ranges from subtle fatigue to life‑threatening thyrotoxic crisis, underscoring the need for precise pharmacologic intervention.

Key drug classes involved include levothyroxine (synthetic T4), liothyronine (synthetic T3), antithyroid agents (methimazole, propylthiouracil), beta‑adrenergic blockers (propranolol, atenolol), and radioactive iodine (I‑131). Each targets distinct aspects of thyroid hormone synthesis, action, or peripheral effects, and their selection hinges on disease etiology, severity, and patient factors.

Mechanism of Action

Levothyroxine (T4) and Liothyronine (T3)

Levothyroxine is a synthetic analogue of thyroxine (T4), the primary hormone secreted by the thyroid gland. It binds to the intracellular thyroid hormone receptor (TR) α and β, forming a heterodimer with the retinoid X receptor (RXR). This complex translocates to the nucleus, where it binds thyroid response elements (TREs) on DNA, modulating transcription of target genes that regulate basal metabolic rate, protein synthesis, and lipid metabolism.

Liothyronine is the active form of triiodothyronine (T3). Unlike T4, which serves largely as a prohormone, T3 directly activates TRs, producing more rapid and potent genomic effects. Both drugs ultimately increase the expression of Na⁺/K⁺‑ATPase, mitochondrial biogenesis, and cytochrome P450 enzymes, thereby elevating metabolic rate.

Antithyroid Drugs (Methimazole & Propylthiouracil)

These agents inhibit thyroid peroxidase (TPO), the enzyme responsible for iodination of tyrosyl residues in thyroglobulin and coupling reactions that form T3 and T4. Methimazole also impedes the iodination of pre‑thyroglobulin, whereas propylthiouracil (PTU) additionally blocks peripheral conversion of T4 to T3 by inhibiting 5‑deiodinase. This dual action renders PTU particularly useful in acute thyrotoxic states.

Beta‑Adrenergic Blockers

Beta blockers mitigate sympathetic manifestations of thyrotoxicosis—tachycardia, tremor, and anxiety—by competitively inhibiting β1 and β2 adrenergic receptors. Propranolol also reduces peripheral conversion of T4 to T3, providing an additional anti‑thyroid effect.

Radioactive Iodine (I‑131)

I‑131 is taken up by the sodium‑iodide symporter (NIS) in thyroid follicular cells. Once inside, its beta radiation induces DNA strand breaks, leading to selective cytotoxicity of hyperactive thyroid tissue. The resultant reduction in hormone synthesis can achieve remission in Graves’ disease and toxic nodules.

Clinical Pharmacology

Understanding pharmacokinetics (PK) and pharmacodynamics (PD) is essential for dose optimization and monitoring. Below are key PK/PD parameters for the principal agents.

Levothyroxine dosing is highly individualized. The starting dose is typically 1.6–1.8 µg/kg/day for adults, adjusted based on TSH and free T4 trends. Liothyronine is reserved for patients with rapid response needs or T4‑resistant hypothyroidism, given its higher potency and shorter half‑life.

Antithyroid drugs are dosed to achieve a target TSH <0.1 mIU/L while minimizing side effects. Methimazole is preferred for long‑term therapy due to lower hepatotoxicity; PTU is indicated in the first trimester of pregnancy and during thyrotoxic crisis because of its 5‑deiodinase inhibition.

Therapeutic Applications

• Hypothyroidism – Levothyroxine is the first‑line agent for all forms, including subclinical, overt, and post‑surgical hypothyroidism. Liothyronine is used when rapid symptom control is needed or T4 therapy is ineffective.

• Hyperthyroidism – Antithyroid drugs (methimazole or PTU) are the cornerstone of medical therapy. Radioactive iodine is the definitive treatment for Graves’ disease and toxic nodular goiter, while beta blockers provide symptomatic control.

• Thyroid Eye Disease – High‑dose glucocorticoids and orbital radiation are adjuncts; antithyroid drugs are contraindicated in severe ocular disease.

• Pregnancy – Levothyroxine is safe; PTU is preferred in the first trimester to reduce fetal exposure to excess T3.

• Pediatric Use – Levothyroxine dosing is weight‑based (2–3 µg/kg/day). Antithyroid drugs are used cautiously, with monitoring for agranulocytosis.

Special populations require dose adjustments: in renal impairment, levothyroxine clearance is reduced, necessitating a 10–20% dose reduction; hepatic impairment may prolong drug half‑life. In the elderly, sensitivity to beta blockers increases, mandating lower initial doses.

Adverse Effects and Safety

Common side effects and incidence rates are summarized below.

• Levothyroxine – Upset stomach (5–10%), insomnia (2–5%), palpitations (1–3%)

• Liothyronine – Tachycardia (10–20%), anxiety (5–10%)

• Methimazole – Rash (5–10%), arthralgia (2–5%), agranulocytosis (0.1%)

• Propylthiouracil – Hepatotoxicity (0.1–0.5%), rash, agranulocytosis (0.1%)

• Beta Blockers – Bradycardia (5–10%), hypotension (2–5%), bronchospasm (1–3%)

• I‑131 – Cold intolerance (5–10%), transient hyperthyroidism (10–15%), radiation safety concerns

Black box warnings include agranulocytosis for antithyroid drugs and radiation safety for I‑131. Drug interactions are critical: levothyroxine should not be co‑administered with calcium or iron supplements within 4 hours; PTU interacts with warfarin, increasing INR; beta blockers may potentiate the effects of ACE inhibitors.

Monitoring parameters include baseline and follow‑up TSH, free T4/T3, CBC for antithyroid drugs, and liver function tests for PTU. Contraindications encompass pregnancy (for PTU in second and third trimesters), severe heart failure (for beta blockers), and uncontrolled agranulocytosis.

Clinical Pearls for Practice

• Start levothyroxine on an empty stomach 30–60 min before breakfast. Food delays absorption; timing improves therapeutic consistency.

• Use PTU only in the first trimester of pregnancy or thyrotoxic crisis. Its 5‑deiodinase inhibition reduces fetal T3 exposure.

• Monitor CBC weekly for the first month on antithyroid drugs. Agranulocytosis presents early; prompt detection saves morbidity.

• Adjust levothyroxine dose by 10–20% in renal insufficiency. Reduced clearance prolongs drug action.

• Beta blockers should be titrated to the lowest effective dose in elderly patients. Sensitivity to bradycardia and hypotension is heightened.

• For Graves’ disease, I‑131 is the definitive therapy; consider surgery if contraindicated. Surgery offers rapid control but carries operative risk.

• Mnemonic: “T3 T4 TSH” – T3/T4 ratios help distinguish primary from secondary hypothyroidism. Elevated TSH with low T4 indicates primary disease.

Comparison Table

Exam‑Focused Review

USMLE Step 2 and Step 3 frequently test the following concepts:

• Distinguishing primary vs. secondary hypothyroidism based on TSH and free T4.

• Identifying the most appropriate antithyroid drug for a patient with Graves’ disease in the first trimester.

• Recognizing the early signs of antithyroid‑drug agranulocytosis and the need for immediate CBC.

• Understanding the rationale for beta‑blocker use in thyrotoxic crisis and the contraindications in heart failure.

• Applying the concept of “washout” periods when switching from levothyroxine to liothyronine or vice versa.

Key differentiators students often confuse:

1. Levothyroxine vs. liothyronine: T4 vs. T3; dosing intervals; side‑effect profiles.

2. Methimazole vs. PTU: hepatic toxicity vs. deiodinase inhibition; pregnancy considerations.

3. I‑131 vs. surgery: definitive therapy vs. immediate control; radiation safety.

Must‑know facts for NAPLEX:

• Levothyroxine dosing is weight‑based; monitor TSH every 6–8 weeks until stable.

• Antithyroid drugs require weekly CBC for the first month; stop if ANC <1 × 10⁹/L.

• Beta blockers are first‑line for symptomatic control; propranolol is preferred for its T4‑to‑T3 inhibition.

• Pregnancy: PTU in 1st trimester; switch to methimazole thereafter; avoid I‑131.

• Radiation safety: patients should avoid close contact with infants for 2 weeks post‑I‑131.

Key Takeaways

1. Levothyroxine remains the gold standard for hypothyroidism; liothyronine is reserved for selective indications.

2. Antithyroid drugs are first‑line for hyperthyroidism; methimazole is preferred except in pregnancy first trimester or crisis.

3. Beta blockers provide symptomatic relief and, in propranolol, reduce peripheral T3 conversion.

4. I‑131 offers definitive ablation but requires post‑treatment monitoring and radiation precautions.

5. Monitoring TSH, free T4/T3, CBC, and liver function is essential for safe therapy.

6. Drug interactions can compromise absorption or increase toxicity; educate patients on timing and food restrictions.

7. Special populations—renal/hepatic impairment, pregnancy, pediatrics—necessitate dose adjustments and careful monitoring.

8. Early recognition of agranulocytosis and hepatic injury is lifesaving; prompt cessation of offending drug is mandatory.

9. Clinical pearls—empty‑stomach dosing, weekly CBC, 10–20% dose reduction in renal disease—enhance patient outcomes.

10. Exam questions frequently probe differentiation between drug classes, dosing algorithms, and safety monitoring.

Always remember: thyroid disorders are treatable, but vigilant monitoring and patient education are the cornerstones of safe, effective therapy.